Abstracts tagged "ROS"

Abstract Number: 1194 • 2014 ACR/ARHP Annual Meeting
Cofilin-1 Is a ROS Sensor in Regulating the NLRP3 Inflammasome
Yong Hwan Park¹, Daniel L. Kastner² and Jae Jin Chae¹, ¹Medical Genetics Branch, National Human Genome Research Institute, Bethesda, MD, ²Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD
Background/Purpose NLRP3 (NOD-like receptor family, pyrin domain containing 3) has a pivotal role in nucleating inflammasome, cytoplasmic multiprotein complexes that mediate the maturation of the…
Abstract Number: 2559 • 2013 ACR/ARHP Annual Meeting
Effect Of NOX4 Overexpression On The Levels Of Micro RNAs Relevant To Systemic Sclerosis Fibrotic Process
Sonsoles Piera-Velazquez, Alma Makul and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Systemic sclerosis (SSc) is characterized by the excessive deposition of collagen and other connective tissue components in skin and multiple internal organs. Although transforming…
Abstract Number: 1827 • 2013 ACR/ARHP Annual Meeting
The Intraarticular Injection Of An Inhibitor Of Complex V Of Mitochondrial Respiratory Chain Induces a Pathological Response In Rat Knee Joints
Carlos Vaamonde-García¹, Jesus Loureiro¹, Eduardo López-Peláez², Alberto Centeno-Cortés², Romina R. Riveiro-Naveira¹, M. Noa Valcárcel-Ares¹, Francisco J. Blanco³ and Maria J. López-Armada¹, ¹Aging and Inflammation Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain, ²Experimental Surgery Unit, CHU A Coruña, A Coruña, Spain, ³Osteoarticular and Aging Res. Lab. CIBER-BBN. INIBIC- University of A Coruña, A Coruña, Spain
Background/Purpose: A decline of mitochondrial function has been described in OA chondrocytes and RA synoviocytes. Recent ex vivo findings support a connection between mitochondrial dysfunction…
Abstract Number: 1160 • 2013 ACR/ARHP Annual Meeting
Oxidative Stress As a Disease Marker and Therapeutic Target In Patients With Tumor Necrosis Factor Receptor Associated Periodic Fever Syndrome
Cornelia Cudrici¹, Ariel Bourla¹, Martin Pelletier², Leah Billingham¹, Amanda K. Ombrello³, Michael Murphy⁴, Daniel L. Kastner⁵ and Richard M. Siegel⁶, ¹NIAMS, Immunoregulation Section, Autoimmunity Branch, Bethesda, MD, ²Niams, Immunoregulation Section, Autoimmunity Branch, Bethesda, MD, ³National Human Genome Research Institute,National Institute of Health, Bethesda, MD, ⁴Medical research council mitochondria biology unit Cambridge ,UK, Cambridge, United Kingdom, ⁵Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

Background/Purpose: TRAPS (Tumor necrosis factors receptor associated periodic fever syndrome) is an autosomal dominant autoinflammatory disease associated with missense mutations in TNFRSF1A (tumor necrosis factor…
Abstract Number: 47 • 2013 ACR/ARHP Annual Meeting
Exogenous Hydrogen Sulfide Donors Show Anti-Catabolic and Anti-Inflammatory Properties But Limited Anti-Oxidant Capability On Human Articular Osteoarthritic Chondrocytes
Elena F. Burguera^1,2, Angela Vela-Anero^2,3, Rosa Meijide-Failde² and Francisco J. Blanco^1,4, ¹Rheumatology Service, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade da Coruña (UDC)., Grupo de Bioingeniería Tisular y Terapia Celular (CBTTC-CHUAC). CIBER-BBN/ISCIII., A Coruña, Spain, ³Department of Medicine, University of A Coruña, A Coruña, Spain, ⁴Tissue Engineering and Cellular Therapy Group (CBTTC-CHUAC), CIBER BBN/ISCIII, A Coruña, Spain
Background/Purpose: Osteoarthritis (OA) is characterized by an imbalance between catabolism and anabolism, higher than normal levels of matrix metalloproteinases (MMPs), an increase in inflammatory markers…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].